Vincent Forlenza, 49, was named president of BD Biosciences of Franklin Lakes, NJ, a Becton Dickinson company. Forlenza, who joined B D in 1980, most recently served as senior vice president for technology, strategy and development. He immediately succeeds Deborah Neff, who is leaving the company to pursue other opportunities, the company said in a statement. Forlenza holds a BS in chemical engineering from Lehigh University, and an MBA from the University of Pennsylvania’s Wharton Graduate School.
Todd Davis of the private equity investor Apax Partners was named to the board of directors of Prometheus Laboratories of San Diego, elected to fill the seat previously held by Janet Effland, who has retired from Apax. Davis is a partner at Apax, focusing on healthcare. Previously, he was vice president for global licensing and business development for Elan Drug Delivery. He holds a BS degree from the US Naval Academy, and an MBA from the Harvard Business School.
Cy Stein has joined the board of directors of CytoGenix of Houston. In addition to serving on the company’s science advisory board, he is also a professor of medicine, urology, and molecular pharmacology at the Albert Einstein College of Medicine. Stein holds a PhD in chemistry from Stanford, and an MD from Albert Einstein. Previously, he was a professor at the College of Physicians and Surgeons of Columbia University.
GeneMachines founder and CEO Scott Hunicke-Smith has stepped down, and Patricia Gray, who was running the R&D department, has been promoted to vice-president of the GeneMachines product and supply division of Genomic Solutions (see story, page 1).
David Riggs was named vice president and chief financial officer for Exegenics of Dallas. He replaces Joan Gillett, vice president, controller and secretary, who leaves the company on April 30 to pursue other interests; and Robert Rousseau, vice president of business development, who left the company in January, the company said. Riggs was most recently the founder and president of Emlin Bioscience.